Vilon is a dipeptide composed of amino acids lysine and glutamic acid. It also goes by the name ‘lysglutamic acid.’(1) It is the shortest peptide suggested to possess potential action in the immune system, possibly mitigate cancer cell proliferation, and potentially induce anti-aging action, working on crucial organs such as the liver, heart, and kidney. Vilon appears to exert its potential by possible interaction with the chromatin structure.
Vilon peptide may exhibit the following actions on chromatin:(2)
- Possibly unrolls the chromatin structures
- May activate ribosomal genes stimulating the synthetic process
- May release inactive genes
- May not decondense the chromatin situated on each side of the centromere of chromosome
Through it’s potential action on the chromatin, Vilon may host potential to alter DNA structure to reactivate the genes and cells that have gone ‘silent.’
Considered a bioregulator peptide, Vilon may have the potential to improve the immune system, especially in immunocompromised subjects.
Researchers suggest Vilon may activate the interleukin-2 protein in spleen cells, which is critical in maintaining immunity.(3) It may stimulate the body to fight against microbial infection and foreign bodies and prevents harmful autoimmune responses. Vilon has been suggested to activate white blood cells and spleen cells and potentially naturally boost the body to protect against autoimmune ailments.
A study was conducted in 2002 with three bioregulatory peptides to study their potential on interleukin-2 mRNA synthesis in spleen cells. According to this study, “The intensity of interleukin-2 mRNA synthesis in splenocytes depended on the type, concentration, and duration of treatment with the peptides. Vilon and Epithalon were most potent, while Cortagen produced a less pronounced effect on interleukin-2 mRNA synthesis.”(3)
Furthermore, Vilon peptides may possibly mitigate autoimmune action by interacting with the thymus gland. The thymus gland is considered responsible for the proliferation of T-helper cells, and with the help of the Vilon peptide, this proliferation may be further enhanced. As per N N Sevostianiva et al., the Vilon peptide is “considered as a bioactive substance possessing immunomodulator and antiallergic activity.” (4)
Research and Clinical Studies
Extended research has produced a wide variety of hypotheses speculating on the action of the Vilon peptide, some detailed below:
Vilon Peptide and Lifespan in Test Models
Vilon may potentially extend the average lifespan of test models. As stated above, Vilon has been suggested to exhibit potential in enhancing the immune system, improving physical endurance and energy levels, thereby possibly increasing average lifespan of experimental test subjects.(5) Vilon is advised to study earlier in the test model lifespan rather than later for clearest possible action. Researchers hypothesize when a bioregulator like Vilon is presented in the later stages of life, it may only potentially reverse ‘silent’ cells, exerting no potential action on cells killed via apoptosis.
Vilon Peptide and Carcinogenic Cells
Several studies suggest that Vilon peptide exhibits potential to prevent some spread of carcinogenic cells by possibly preventing the formation of new tumors but also potentially inhibiting existing tumors’ growth. (6)
One study contradicts this potential property of Vilon. As per this study, when used with chemotherapeutic agents derived from platinum ions, this peptide–platinum combination may be more harmful than helpful.  Unfortunately, since this study only considers one specific type of chemotherapeutic action, study results reported by researchers may be inconclusive.
Vilon Peptide and GI Tract Function
Vilon peptide may act on gastrointestinal functionality via possibly enhancing working mechanisms of certain enzymes in the gastrointestinal tract. By doing so, the peptide exhibits potential body resistance towards GI-specific ailments, reduces leaky bowels in test subjects.. [8) Acting on the small intestinal muscles, Vilon peptide may ameliorate glucose accumulation and glycine absorption. (9)
Vilon Peptide and Gene Expression
Upon presenting the Vilon peptide, reserachers have suggested it exhibits potential in test subjects to alter the gene expression of 36 genes in the heart. When presented with Epithalon, this number reported was 144 genes. This suggests the peptide’s possible action on genetic expression in the cardiac system, possibly impacting hemodynamic properties.. [10)
Vilon Peptide and Fibrinolysis
Researchers suggested in one study that Vilon exhibits potential to stimulate fibrinolysis and increase the concentration of natural anticoagulants in the body, namely antithrombin III and protein C. It was also suggested to reduce insulin levels and possibly regulate the metabolism of carbohydrates.(11) Vilon is suggested to increase the permeability of mesenteric microvessels in the vascular system. As per N. Gavrisheva et al., these results indicate that “the preparation produces a potent homeostatic effect in the early period of chronic renal failure.”(12)
Vilon peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.
- National Center for Biotechnology Information (2022). PubChem Compound Summary for CID 7010502, Lysylglutamic acid. Retrieved November 21, 2022 from https://pubchem.ncbi.nlm.nih.gov/compound/Lysylglutamic-acid
- Lezhava T, Khavison V, Monaselidze J, Jokhadze T, Dvalishvili N, Bablishvili N, Barbakadze S. Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people. Biogerontology. 2004;5(2):73-9. https://pubmed.ncbi.nlm.nih.gov/15105581/
- Kazakova TB, Barabanova SV, Khavinson VKh, Glushikhina MS, Parkhomenko EP, Malinin VV, Korneva EA. In vitro effect of short peptides on expression of interleukin-2 gene in splenocytes. Bull Exp Biol Med. 2002 Jun;133(6):614-6. https://pubmed.ncbi.nlm.nih.gov/12447482/
- Sevostianova NN, Linkova NS, Polyakova VO, Chervyakova NA, Kostylev AV, Durnova AO, Kvetnoy IM, Abdulragimov RI, Khavinson VH. Immunomodulating effects of Vilon and its analogue in the culture of human and animal thymus cells. Bull Exp Biol Med. 2013 Feb;154(4):562-5. English, Russian. https://pubmed.ncbi.nlm.nih.gov/23486604/
- Khavinson VK, Anisimov VN, Zavarzina NY, Zabezhinskii MA, Zimina OA, Popovich IG, Shtylik AV, Malinin VV, Morozov VG. Effect of vilon on biological age and lifespan in mice. Bull Exp Biol Med. 2000 Jul;130(7):687-90. DOI: 10.1007/BF02682106. PMID: 11140587. https://pubmed.ncbi.nlm.nih.gov/11140587/
- Khavinson VKh, Anisimov VN. A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits the growth of spontaneous tumors and increases the life span of mice. Dokl Biol Sci. 2000 May-Jun;372:261-3. PMID: 10944717. https://pubmed.ncbi.nlm.nih.gov/10944717/
- Barykina OP, Iuzhakov VV, Chalisova NI, Kvetnoĭ IM, Konovalov SS. Sochetannoe vliianie vilona i tsiklofosfana na transplanty opukholeĭ i éksplantaty limfoidnoĭ tkani mysheĭ i krys raznogo vozrasta [Combined effect of vilon and cyclophosphane on tumor transplants and lymphoid tissue explants in mice and rats of various age]. Adv Gerontol. 2003;12:128-31. Russian. PMID: 14743610. https://pubmed.ncbi.nlm.nih.gov/14743610/
- Khavinson VKh, Timofeeva NM, Malinin VV, Cordova LA, Nikitina AA. Effect of vilon and epithalon on activity of enzymes in epithelial and subepithelial layers in small intestine of old rats. Bull Exp Biol Med. 2002 Dec;134(6):562-4. https://pubmed.ncbi.nlm.nih.gov/12660839/
- Khavinson VKh, Egorova VV, Timofeeva NM, Malinin VV, Cordova LA, Gromova LV. Effect of Vilon and Epithalon on glucose and glycine absorption in various regions of small intestine in aged rats. Bull Exp Biol Med. 2002 May;133(5):494-6. https://pubmed.ncbi.nlm.nih.gov/12420071/
- Anisimov SV, Bokheler KR, Khavinson VKh, Anisimov VN. Studies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology. Bull Exp Biol Med. 2002 Mar;133(3):293-9. https://pubmed.ncbi.nlm.nih.gov/12360356/
- Kuznik BI, Isakova NV, Kliuchereva NN, Maleeva NV, Pinelis IS. [Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus]. Adv Gerontol. 2007;20(2):106-15. Russian. PMID: 18306698. https://pubmed.ncbi.nlm.nih.gov/18306698/
- Gavrisheva NA, Malinin VV, Ses TP, Kozlov KL, Panchenko AV, Titkov AY. Effect of peptide Vilon on the content of transforming growth factor-beta and permeability of microvessels during experimental chronic renal failure. Bull Exp Biol Med. 2005 Jan;139(1):24-6. DOI: 10.1007/s10517-005-0202-9. PMID: 16142267. https://pubmed.ncbi.nlm.nih.gov/16142267/
NOTE: These products are intended for laboratory research use only. Vilon for sale (20mg) is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.
Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.